Nothing Special   »   [go: up one dir, main page]

SI2177224T1 - Spojina za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RyR receptorjev - Google Patents

Spojina za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RyR receptorjev

Info

Publication number
SI2177224T1
SI2177224T1 SI200631575T SI200631575T SI2177224T1 SI 2177224 T1 SI2177224 T1 SI 2177224T1 SI 200631575 T SI200631575 T SI 200631575T SI 200631575 T SI200631575 T SI 200631575T SI 2177224 T1 SI2177224 T1 SI 2177224T1
Authority
SI
Slovenia
Prior art keywords
preventing
compound
treating disorders
disorders involving
involving modulation
Prior art date
Application number
SI200631575T
Other languages
English (en)
Inventor
Andrew R. Marks
Donald W. Landry
Shixian Deng
Zhen Zhuang Cheng
Stephan E. Lehnart
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of SI2177224T1 publication Critical patent/SI2177224T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
SI200631575T 2005-08-25 2006-08-17 Spojina za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RyR receptorjev SI2177224T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/212,413 US7704990B2 (en) 2005-08-25 2005-08-25 Agents for preventing and treating disorders involving modulation of the RyR receptors
EP09013475A EP2177224B1 (en) 2005-08-25 2006-08-17 Compound for preventing and treating disorders involving modulation of the RyR receptors

Publications (1)

Publication Number Publication Date
SI2177224T1 true SI2177224T1 (sl) 2013-06-28

Family

ID=37772221

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200631576T SI2311464T1 (sl) 2005-08-25 2006-08-17 Učinkovine za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RyR receptorjev
SI200631612T SI1928850T1 (sl) 2005-08-25 2006-08-17 Učinkovine za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RYR receptorjev
SI200631575T SI2177224T1 (sl) 2005-08-25 2006-08-17 Spojina za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RyR receptorjev

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200631576T SI2311464T1 (sl) 2005-08-25 2006-08-17 Učinkovine za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RyR receptorjev
SI200631612T SI1928850T1 (sl) 2005-08-25 2006-08-17 Učinkovine za preprečevanje in zdravljenje nepravilnosti, ki vključujejo modulacijo RYR receptorjev

Country Status (35)

Country Link
US (1) US7704990B2 (sl)
EP (4) EP2311464B1 (sl)
JP (1) JP5342877B2 (sl)
KR (2) KR101456342B1 (sl)
CN (2) CN102558093B (sl)
AP (1) AP3091A (sl)
AR (1) AR057776A1 (sl)
AU (1) AU2006283534C1 (sl)
BR (1) BRPI0615097B1 (sl)
CA (1) CA2620183C (sl)
CR (1) CR9812A (sl)
CY (3) CY1113975T1 (sl)
DK (3) DK2177224T3 (sl)
EA (1) EA014941B1 (sl)
EC (1) ECSP088306A (sl)
ES (3) ES2405780T3 (sl)
GE (1) GEP20105134B (sl)
HK (3) HK1119705A1 (sl)
HN (1) HN2008000299A (sl)
HR (3) HRP20130353T1 (sl)
IL (1) IL189675A (sl)
MA (1) MA29785B1 (sl)
MY (1) MY144622A (sl)
NO (1) NO20081421L (sl)
NZ (1) NZ566822A (sl)
PL (3) PL2177224T3 (sl)
PT (3) PT1928850E (sl)
RS (3) RS52780B (sl)
SI (3) SI2311464T1 (sl)
SV (1) SV2008002828A (sl)
TN (1) TNSN08078A1 (sl)
TW (1) TWI486338B (sl)
UA (1) UA93388C2 (sl)
WO (1) WO2007024717A2 (sl)
ZA (1) ZA200802338B (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) * 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004080283A2 (en) * 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008144483A2 (en) * 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
DK2250159T3 (da) 2008-03-03 2012-03-19 Servier Lab Fremgangsmåde til fremstilling af benzothiazepiner fra gamma-amino-alkylbenzener
AU2008243144A1 (en) * 2008-11-06 2010-05-20 Quark Technologies Australia Pty Ltd Improvements in Radiopharmaceutical Purification
WO2010098080A1 (ja) * 2009-02-25 2010-09-02 Kaneko Noboru １，４－ベンゾチアゼピン－１－オキシド誘導体、及びそれを用いた医薬組成物
EP2418950A4 (en) * 2009-04-15 2012-10-24 State Of Oregon By & Through The State Board Of Higher Education On Behalf Of Portland State Unv COMPOUNDS AND METHODS FOR MODULATING THE ACTIVITY OF CALCIUM RELEASE CHANNELS
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
US9464322B2 (en) 2011-09-09 2016-10-11 University Of Kentucky Research Foundation Methods for diagnosing and treating alzheimer's disease (AD) using the molecules that stabilize intracellular calcium (Ca2+) release
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
WO2016168694A1 (en) * 2015-04-15 2016-10-20 Ohio State Innovation Foundation Engineered calmodulin for treatment of ryanopathies
ES2643856B1 (es) * 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
CN109328018A (zh) 2016-12-15 2019-02-12 雀巢产品技术援助有限公司 调节伴侣动物体内的磷或酶的组合物和方法
EP3648755A4 (en) * 2017-07-06 2021-10-20 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO VENTRICULAR TACHYCARDIA POLYMORPHIC CATECHOLAMINERGIC
CN108588085B (zh) * 2018-05-30 2021-11-09 上海市第十人民医院 恶性心律失常的筛查试剂盒、动物模型的建立方法及应用
US11129871B1 (en) 2018-06-19 2021-09-28 Washington University Compositions and methods for treating and preventing endoplasmic reticulum (ER) stress-mediated kidney diseases
JP7595011B2 (ja) 2019-07-22 2024-12-05 株式会社アエタスファルマ 光学活性な１，４－ベンゾチアゼピン－１－オキシド誘導体の製造方法
MX2023008042A (es) 2021-01-08 2023-09-11 Armgo Pharma Inc Formas cristalinas de un modulador del receptor de rianodina y usos del mismo.
WO2022246114A2 (en) 2021-05-20 2022-11-24 Armgo Pharma, Inc. Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) * 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
US3519647A (en) 1966-10-12 1970-07-07 Squibb & Sons Inc 2,3,4,5-tetrahydro-1,5-benzothiazepines
DE3561317D1 (en) * 1984-01-27 1988-02-11 Ajinomoto Kk Manufacture of heptanoic acid derivatives
EP0238700B1 (en) 1986-03-27 1991-01-23 Topy Industries, Limited Carbon monoxide oxidizing catalyst
US4567254A (en) * 1984-09-19 1986-01-28 Kikkoman Corporation Method for preparing N6,8-disubstituted 3',5'-cyclic adenosine monophosphate and salt thereof
US4849535A (en) 1985-02-26 1989-07-18 Ajinomoto Co., Inc. Production of cyclopentenylheptanoic acid derivatives
US4841055A (en) * 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
US4723012A (en) * 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
JPS63227599A (ja) 1987-03-14 1988-09-21 Kirin Brewery Co Ltd アンスラサイクリン化合物およびその用途
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
US5179125A (en) * 1987-12-03 1993-01-12 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
US5272164A (en) 1988-12-27 1993-12-21 Kirin Beer Kabushiki Kaisha Carboximidamide derivatives
JPH0662567B2 (ja) 1988-12-27 1994-08-17 麒麟麦酒株式会社 ピリジンカルボキシイミダミド誘導体、その製造中間体、製造法および用途
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
US5142647A (en) 1989-04-18 1992-08-25 Japan Tobacco, Inc. Magnus measuring apparatus
CA1341094C (en) * 1989-09-25 2000-09-05 Ronald G. Worton Diagnosis for malignant hyperthermia
EP0446374B1 (en) * 1989-09-30 1996-02-07 Kirin Beer Kabushiki Kaisha Method of producing seedling
US5153184A (en) 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5075293A (en) 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
KR940000166B1 (ko) * 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US4963671A (en) 1989-11-20 1990-10-16 E. R. Squibb & Sons, Inc. Process for resolving chiral intermediates used in making calcium channel blockers
EP0460239A4 (en) * 1989-12-27 1992-05-06 Japan Tobacco Inc. 1,3,2-dioxathiolane oxide derivative
US5204462A (en) * 1990-03-30 1993-04-20 Japan Tobacco, Inc. 4h-3,1-benzoxazin-4-one derivative
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
US5082847A (en) 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility
US5064810A (en) 1990-09-14 1991-11-12 Jeffrey Askanazi Use of branched chain amino acids to effect diaphragm contractility and fatigue
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
EP0533951A4 (en) 1991-04-10 1993-09-01 Japan Tobacco Inc. Novel oxazinone derivative
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
ATE180830T1 (de) 1991-07-04 1999-06-15 Japan Tobacco Inc Verfahren zur kultivierung von vorläufer t- zellinien
US5593988A (en) * 1991-10-11 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Therapeutic agent for osteoporosis and diazepine compound
AU3143593A (en) * 1991-12-20 1993-07-28 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin E2 antagonists
MX9300433A (es) * 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
US5387684A (en) * 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
JP3093419B2 (ja) 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
RU94046317A (ru) 1992-07-02 1996-10-20 Фудзисава Фармасьютикал Ко. Новое синтетическое промежуточное соединение для получения производных и способы получения производных аминокислот
WO1994004523A1 (en) * 1992-08-21 1994-03-03 Japan Tobacco Inc. Dioxacycloalkane compound with renin-inhibiting activity
US5260286A (en) 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
NZ257843A (en) 1992-11-09 1996-10-28 Boots Co Plc 2,3,4,5-tetrahydro-1,4-benzothiazepine derivatives optionally substituted in position-6 by methyl, fluoro or chloro
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
ZA94284B (en) * 1993-01-27 1994-08-17 Shionogi & Co Process for preparing benzothiazepine derivatives
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP4020958B2 (ja) 1993-04-15 2007-12-12 キリンファーマ株式会社 新規スフィンゴ糖脂質およびその使用
US5461047A (en) 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
JP3437577B2 (ja) 1993-08-19 2003-08-18 日本たばこ産業株式会社 植物由来のａｔｐ依存フルクトース６リン酸１ホスホトランスフェラーゼをコードするｄｎａ，それを含む組換えベクター及びそれを用いる低温下で植物細胞中の糖含量を変化させる方法
FR2709753B1 (fr) 1993-09-09 1995-12-01 Hoechst Lab Nitrates organiques, leur procédé de préparation et leur application comme médicaments.
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
US5719155A (en) * 1993-11-10 1998-02-17 Japan Tobacco Inc. Chroman derivative and pharmaceutical use thereof
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) * 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5449675A (en) 1994-06-09 1995-09-12 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
US20040175814A1 (en) 1994-06-15 2004-09-09 Kirin Beer Kubushiki Kaisha Novel transferase and amylase, process for producing the enzymes, use thereof, and gene coding for the same
DE69534685T2 (de) * 1994-06-15 2006-09-07 Kirin Beer K.K. Transferase und amylase, verfahren zur herstellung dieser enzyme, ihre verwendung und für die kodierende gene
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
WO1996015152A1 (fr) 1994-11-11 1996-05-23 International Reagents Corporation Anticorps monoclonal antiannexine-v, procede pour produire cet anticorps, et utilisation de cet anticorps
CA2205173A1 (en) 1994-11-18 1996-05-30 Takeshi Nakamura Therapeutic agent for osteoporosis and triazepine compound
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US6660837B1 (en) 1995-09-14 2003-12-09 Kirin Beer Kabushiki Kaisha Modified protein derived from protein kinase N
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
ES2364179T3 (es) 1996-07-08 2011-08-26 Kyowa Hakko Kirin Co., Ltd. Compuestos con actividad receptora de calcio.
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
US6111072A (en) 1996-08-26 2000-08-29 Kirin Beer Kabushiki Kaisha Rho target protein human mDia and gene encoding same
WO1998026053A1 (en) * 1996-12-12 1998-06-18 Kirin Beer Kabushiki Kaisha NOVEL β1→4 N-ACETYLGLUCOSAMINYLTRANSFERASE AND GENE ENCODING THE SAME
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
DE19722317C1 (de) 1997-05-28 1998-10-08 Boehringer Ingelheim Int Das Protein des humanen Ryanodinrezeptors vom Typ 3 sowie dafür kodierende DNA-Moleküle
AUPO941497A0 (en) 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
CA2274776C (en) 1997-10-08 2008-11-25 Noboru Kaneko Method for analyzing annexin v in urine and use thereof
GB9724813D0 (en) 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
EP1043335A4 (en) * 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6051714A (en) 1998-03-12 2000-04-18 Reilly Industries, Inc. Processes for dechlorinating pyridines
AU754716B2 (en) * 1998-03-26 2002-11-21 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
TR200002904T2 (tr) * 1998-04-10 2001-02-21 Japan Tobacco Inc. Amidin bileşikleri
WO1999063984A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel sodium channel drugs and uses
US6890531B1 (en) * 1998-07-31 2005-05-10 Kirin Beer Kabushiki Kaisha Neuronal growth factor galectin-1
AU5651799A (en) 1998-09-17 2000-04-10 Nippon Kayaku Kabushiki Kaisha Remedies for photochemotherapy
US6506745B1 (en) * 1998-12-28 2003-01-14 Noboru Kaneko Medicinal compositions for treatment of atrial fibrillation
WO2000058499A1 (fr) * 1999-03-30 2000-10-05 Japan Tobacco Inc. Procede pour la production d'anticorps monoclonal
KR100686617B1 (ko) 1999-05-19 2007-02-23 가네꼬 노보루 1,4-벤조티아제핀유도체의 항암제 내성극복의약조성물
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
DE60032620T2 (de) * 1999-09-30 2007-10-04 Kaneko, Noboru Antikrebsmittel
TWI281915B (en) 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
AU2733301A (en) * 1999-12-29 2001-07-09 Glaxo Group Limited Methods and compositions related to modulators of annexin and cartilage homeostasis
WO2001051923A2 (en) 2000-01-14 2001-07-19 Mitokor Screening assays using intramitochondrial calcium
US6906072B1 (en) * 2000-01-20 2005-06-14 Eisai Co., Ltd. Piperazine compound and pharmaceutical composition containing the compound
AU2001228810A1 (en) * 2000-01-26 2001-08-07 Ono Pharmaceutical Co. Ltd. Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
ATE420878T1 (de) 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
CA2402436C (en) 2000-03-24 2010-02-16 Pharmacia Corporation Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6489125B1 (en) 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040229781A1 (en) 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
AU2001261434A1 (en) 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
RU2262511C2 (ru) 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU2001267879A1 (en) 2000-07-05 2002-01-14 Ajinomoto Co., Inc. Acylsulfonamide derivatives
WO2002002101A1 (fr) 2000-07-05 2002-01-10 Ajinomoto Co., Inc. Composes hypoglycemiques
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
NZ523770A (en) 2000-08-01 2004-11-26 Pharmacia Corp Hexahydro-7-1H-azepin-2-YL-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase
MY131964A (en) * 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031608A1 (es) 2000-09-15 2003-09-24 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
US6936426B2 (en) * 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
CA2430013C (en) * 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US6673904B2 (en) * 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
WO2002061076A1 (en) * 2001-02-01 2002-08-08 Mochida Pharmaceutical Co., Ltd. Adiponectin-associated protein
JP4817514B2 (ja) 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
CA2440374A1 (en) 2001-03-14 2002-09-19 Takayuki Maruyama A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
WO2002078625A2 (en) 2001-03-28 2002-10-10 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
NZ529046A (en) * 2001-04-27 2005-10-28 Kirin Brewery Quinoline derivative having azolyl group and quinazoline derivative
JP4230681B2 (ja) 2001-07-06 2009-02-25 株式会社東芝 高耐圧半導体装置
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP4269052B2 (ja) * 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド 連結ビアリール化合物
JP2003095977A (ja) * 2001-09-21 2003-04-03 Masafumi Yano 筋肉収縮・弛緩機能障害関連疾患の治療又は予防剤
EP1452093A4 (en) 2001-11-15 2007-08-15 Kirin Brewery CHIMESE NON-MENTAL ANIMAL
JP2003145746A (ja) * 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
AU2002354056A1 (en) 2001-11-19 2003-06-10 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
WO2003061699A1 (fr) 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
US20040171613A1 (en) 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
JP2005521653A (ja) * 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
CN100543022C (zh) 2002-02-01 2009-09-23 大日本住友制药株式会社 2-呋喃甲酸酰肼化合物及含该化合物的药物组合物
US20060233902A1 (en) 2002-02-14 2006-10-19 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
WO2003090570A1 (fr) * 2002-04-26 2003-11-06 Japan Tobacco Inc. Dispositif de fabrication d'articles en forme de barre
US7439332B2 (en) 2002-04-26 2008-10-21 Kirin Pharma Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells
JP4113042B2 (ja) * 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
CZ2004627A3 (cs) * 2002-08-30 2004-10-13 Japanátobaccoáinc Dibenzylaminové sloučeniny a jejich farmaceutické použití
JP2004103256A (ja) 2002-09-04 2004-04-02 Nippon Chemicon Corp 非常灯
JPWO2004024717A1 (ja) 2002-09-12 2006-01-05 麒麟麦酒株式会社 キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
EP1541153A1 (en) 2002-09-20 2005-06-15 Kirin Beer Kabushiki Kaisha Hepatitis c virus inhibitor comprising alpha-glycosylceramide as the active ingredient
EP1559782B1 (en) 2002-10-04 2016-12-21 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome (hac) vector
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004042389A2 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
AU2003293006A1 (en) 2002-11-22 2004-06-18 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
EP1439221B1 (en) 2002-12-17 2007-01-24 F. Hoffmann-La Roche Ag PDE core construct
MXPA05008619A (es) 2003-02-13 2005-11-04 Banyu Pharma Co Ltd Derivados novedosos de 2-piridincarboxamida.
WO2004080283A2 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
TWI220798B (en) 2003-03-07 2004-09-01 Hitachi Cable Light-emitting diode array
ES2377121T3 (es) 2003-03-17 2012-03-22 Japan Tobacco Inc. Composiciones farmacéuticas de inhibidores de CETP
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
JP4926473B2 (ja) 2003-03-27 2012-05-09 協和発酵キリン株式会社 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
BRPI0409136A (pt) 2003-04-09 2006-04-25 Japan Tobacco Inc composto heteroaromático pentacìclico e uso medicinal do mesmo
US20060135506A1 (en) 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20050009733A1 (en) * 2003-04-22 2005-01-13 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
US20040229803A1 (en) 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20050159403A1 (en) 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
US20050187221A1 (en) 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
WO2005063247A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Aryl sulfonamide compounds and uses related thereto
US7165879B2 (en) 2004-03-25 2007-01-23 Red Devil Equipment Company Clamp lock apparatus and method for a paint mixer
JP2007533328A (ja) * 2004-04-22 2007-11-22 キリンホールディングス株式会社 トランスジェニック動物及びその用途
AU2005238389B2 (en) 2004-04-28 2009-08-06 Aetas Pharma Co., Ltd. Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) * 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
NZ552086A (en) * 2004-07-15 2009-12-24 Japan Tobacco Inc Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor
JP2006094849A (ja) 2004-08-30 2006-04-13 Kirin Brewery Co Ltd 相同組換え効率が向上した分化多能性細胞及びその利用
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP2008531579A (ja) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強利尿化合物、組成物および使用方法
WO2006093247A1 (ja) 2005-02-28 2006-09-08 Japan Tobacco Inc. Ｓｙｋ阻害活性を有する新規なアミノピリジン化合物
WO2006098394A1 (ja) 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
TWI486338B (zh) 2015-06-01
UA93388C2 (uk) 2011-02-10
NO20081421L (no) 2008-05-23
RS52852B (en) 2013-12-31
EP2311464A1 (en) 2011-04-20
DK1928850T3 (da) 2013-09-23
RS52781B (en) 2013-10-31
PT1928850E (pt) 2013-08-23
EP1928850A2 (en) 2008-06-11
BRPI0615097A2 (pt) 2009-07-14
HRP20130353T1 (hr) 2013-06-30
SI2311464T1 (sl) 2013-06-28
EA200800665A1 (ru) 2008-08-29
CN102558093A (zh) 2012-07-11
TNSN08078A1 (en) 2009-07-14
CY1113975T1 (el) 2016-07-27
EP2311464B1 (en) 2013-02-13
EP2764867A1 (en) 2014-08-13
WO2007024717A2 (en) 2007-03-01
PL1928850T3 (pl) 2013-11-29
KR101456342B1 (ko) 2014-11-03
CY1113974T1 (el) 2016-07-27
WO2007024717A3 (en) 2009-01-08
HRP20130360T1 (hr) 2013-06-30
AR057776A1 (es) 2007-12-19
US7704990B2 (en) 2010-04-27
HN2008000299A (es) 2011-07-11
ES2405765T3 (es) 2013-06-03
PT2311464E (pt) 2013-05-15
PT2177224E (pt) 2013-05-15
PL2311464T3 (pl) 2013-07-31
CY1114091T1 (el) 2016-07-27
TW200800930A (en) 2008-01-01
GEP20105134B (en) 2010-12-27
IL189675A0 (en) 2008-06-05
KR20120025626A (ko) 2012-03-15
MA29785B1 (fr) 2008-09-01
EP2177224B1 (en) 2013-02-27
HRP20130669T1 (hr) 2013-08-31
EP1928850A4 (en) 2009-06-17
JP5342877B2 (ja) 2013-11-13
CN101500576B (zh) 2013-08-14
JP2009506034A (ja) 2009-02-12
EA014941B1 (ru) 2011-04-29
RS52780B (en) 2013-10-31
CA2620183C (en) 2014-04-15
ZA200802338B (en) 2009-01-28
BRPI0615097B1 (pt) 2021-06-01
AU2006283534B2 (en) 2010-11-04
IL189675A (en) 2013-12-31
KR20080037741A (ko) 2008-04-30
EP2177224A2 (en) 2010-04-21
HK1137150A1 (en) 2010-07-23
ECSP088306A (es) 2008-07-30
CN102558093B (zh) 2014-10-15
DK2177224T3 (da) 2013-05-13
CA2620183A1 (en) 2007-03-01
DK2311464T3 (da) 2013-05-13
AP3091A (en) 2015-01-31
US20070049572A1 (en) 2007-03-01
PL2177224T3 (pl) 2013-07-31
SV2008002828A (es) 2010-07-20
HK1153664A1 (en) 2012-04-05
CR9812A (es) 2009-09-14
NZ566822A (en) 2011-04-29
EP1928850B1 (en) 2013-06-19
AU2006283534C1 (en) 2012-08-02
ES2405780T3 (es) 2013-06-03
ES2421159T3 (es) 2013-08-29
AU2006283534A1 (en) 2007-03-01
CN101500576A (zh) 2009-08-05
SI1928850T1 (sl) 2013-09-30
EP2177224A3 (en) 2010-06-30
HK1119705A1 (en) 2009-03-13
MY144622A (en) 2011-10-14

Similar Documents

Publication Publication Date Title
HRP20130360T1 (hr) Sredstva za prevenciju i lijeäśenje poremeä†aja koji obuhvaä†aju modulaciju ryr receptora
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL185016A0 (en) Compounds for the treatment of proliferative disorders
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200700918B (en) Compositions and methods for treating eye disorders and conditions
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
HK1119577A1 (en) Compounds for the treatment of metabolic disorders
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1755637A4 (en) METHODS FOR PREVENTING OR TREATING BONE DISEASES
EP1858557A4 (en) METHODS AND COMPOSITIONS FOR MODULATING BODY WEIGHT AND TREATING WEIGHT RELATED DISORDERS AND DISEASES
ZA200410080B (en) Composition for the treatment of humans
ZA200805859B (en) Methods and compositions for the treatment of gastriontestinal disorders
GB2441581B (en) Compositions and methods for the treatment of muscle wasting
TJ20050863A (en) The way of narcotism treatment
IL185684A0 (en) Methods and compositions for modulating body weight and for treating weight disorders and related diseases
GB0507552D0 (en) Methods and compounds for the treatment of cognitive dysfunction